The global artificial intelligence in drug development and discovery market is segmented on the basis of drug type, technology, application, end user, and region. Based on drug type, the market is divided into small molecules and large molecules. Based on technology the market is classified into deep learning and machine learning. Based on application, the market is segmented into oncology, cardiovascular disease, neurodegenerative disease, metabolic disease, and others. On the basis of region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, and rest of Asia-Pacific), and LAMEA (Latin America, Middle East, and Africa). Key Benefits for World Artificial intelligence in drug development and discovery market: It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities. The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the market. A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities. The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.